A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1SPT-300 (GlyphAllo) is being tested in a Phase 2 trial, which means its safety and effectiveness are still being established — given that, what do we currently know about its safety profile, and how does that uncertainty compare to antidepressants I could start right now?
2. 2This trial measures depression symptoms using the HAM-D-17 scale at 42 days — does a 6-week timeframe actually give us enough information about whether a treatment is working for my type of depression, especially if I also have anxious distress?
3. 3The trial includes people both with and without anxious distress — based on my specific symptoms, do you think I'd be more likely to benefit from a study like this, or would a more targeted existing treatment be a better first step?
4. 4Since this is still a recruiting Phase 2 study, there's no published efficacy data yet — would it make sense for me to try a standard antidepressant first and consider a trial like this if that doesn't work, or is there a reason to think about it now?
5. 5What would participation in this trial actually look like for my day-to-day life over those 42 days — how many visits, what kind of monitoring, and what happens if my depression worsens during the study?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.